Similar articles

• Chronic kidney disease, anemia, and epoetin.

  Riley DS. Riley DS. N Engl J Med. 2007 Mar 1;356(9):956; author reply 958-9. doi: 10.1056/NEJMc063535. N Engl J Med. 2007. PMID: 17329706 No abstract available.
• Chronic kidney disease, anemia, and epoetin.

  Ashrani AA, Rajkumar SV. Ashrani AA, et al. N Engl J Med. 2007 Mar 1;356(9):957-8; author reply 958-9. N Engl J Med. 2007. PMID: 17338048 No abstract available.
• Correction of anemia--payoffs and problems.

  Remuzzi G, Ingelfinger JR. Remuzzi G, et al. N Engl J Med. 2006 Nov 16;355(20):2144-6. doi: 10.1056/NEJMe068233. N Engl J Med. 2006. PMID: 17108347 No abstract available.
• Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality.

  Jones M, Schenkel B, Just J. Jones M, et al. Int J Cardiol. 2005 Apr 20;100(2):253-65. doi: 10.1016/j.ijcard.2004.08.051. Int J Cardiol. 2005. PMID: 15823633 Review.
• Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.

  Shah HH, Fishbane S. Shah HH, et al. Adv Chronic Kidney Dis. 2019 Jul;26(4):267-271. doi: 10.1053/j.ackd.2019.04.007. Adv Chronic Kidney Dis. 2019. PMID: 31477257 Review.